Nova Eye Medical Ltd (ASX: EYE) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Nova Eye Medical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$34.36 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
229.07 million
Earnings per share
-0.043
Dividend per share
N/A
Year To Date Return
-35.81%
Earnings Yield
N/A
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Nova Eye Medical Ltd (ASX: EYE)
Latest News
⏸️ Investing
The Ellex Medical Lasers Limited share price is climbing higher
⏸️ Investing
Why these 4 ASX shares have jumped higher today
⏸️ Investing
Warren Buffett is Backing Trump's "Miracle Economy" And Loading Up On Stocks
⏸️ Investing
Why these 4 shares are getting SMASHED today
⏸️ Investing
Why the Ellex Medical Lasers Limited share price was SMASHED today
⏸️ Investing
Why Ellex Medical Lasers Limited shares have surged higher today
⏸️ Investing
Why small-cap Alcidion Group Ltd has gone gangbusters this month
⏸️ Investing
4 stocks soaring on the ASX today
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 21 Jul 2020 | $0.1350 | 100.00% | Special Cash | 29 Jul 2020 |
EYE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Nova Eye Medical Ltd
Nova Eye Medical Ltd is a medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of its revenue from the United States of America.
EYE Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 27 Dec 2024 | $0.15 | $0.00 | 0.00% | 4,570 | $0.16 | $0.16 | $0.15 |
| 24 Dec 2024 | $0.15 | $0.00 | 0.00% | 124,458 | $0.15 | $0.16 | $0.15 |
| 23 Dec 2024 | $0.15 | $0.01 | 6.90% | 69,900 | $0.15 | $0.15 | $0.15 |
| 20 Dec 2024 | $0.15 | $-0.01 | -6.45% | 86,747 | $0.15 | $0.15 | $0.15 |
| 19 Dec 2024 | $0.16 | $0.00 | 0.00% | 31,606 | $0.15 | $0.16 | $0.15 |
| 18 Dec 2024 | $0.16 | $0.01 | 6.90% | 241,106 | $0.15 | $0.16 | $0.15 |
| 17 Dec 2024 | $0.15 | $0.00 | 0.00% | 227,304 | $0.14 | $0.15 | $0.14 |
| 16 Dec 2024 | $0.14 | $0.00 | 0.00% | 306,182 | $0.14 | $0.14 | $0.14 |
| 13 Dec 2024 | $0.14 | $0.00 | 0.00% | 95,186 | $0.15 | $0.15 | $0.14 |
| 12 Dec 2024 | $0.14 | $-0.01 | -6.78% | 607,187 | $0.15 | $0.15 | $0.14 |
| 11 Dec 2024 | $0.15 | $0.00 | 0.00% | 202,915 | $0.15 | $0.15 | $0.15 |
| 10 Dec 2024 | $0.15 | $-0.01 | -6.45% | 36,081 | $0.16 | $0.16 | $0.15 |
| 09 Dec 2024 | $0.16 | $0.00 | 0.00% | 173,563 | $0.16 | $0.16 | $0.15 |
| 06 Dec 2024 | $0.16 | $-0.01 | -6.25% | 88,455 | $0.16 | $0.16 | $0.16 |
| 05 Dec 2024 | $0.16 | $0.01 | 6.45% | 468,906 | $0.16 | $0.16 | $0.15 |
| 04 Dec 2024 | $0.16 | $0.00 | 0.00% | 307,211 | $0.15 | $0.16 | $0.15 |
| 03 Dec 2024 | $0.16 | $0.01 | 6.67% | 117,501 | $0.16 | $0.16 | $0.16 |
| 02 Dec 2024 | $0.15 | $-0.01 | -6.45% | 204,089 | $0.16 | $0.16 | $0.15 |
| 29 Nov 2024 | $0.16 | $0.00 | 0.00% | 61,380 | $0.16 | $0.16 | $0.15 |
| 28 Nov 2024 | $0.16 | $0.01 | 6.90% | 387,081 | $0.15 | $0.16 | $0.15 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 Nov 2024 | Thomas (Tom) Spurling | Issued | 300,000 | $46,500 |
Issue of securities. Performance Rights 300,000
|
| 27 Nov 2024 | Thomas (Tom) Spurling | Expiry | 700,000 | $101,500 |
Options expired. As per announcement on 27-11-2024
|
| 15 Mar 2024 | Rahmon Coupe | Issued | 149,022 | $31,294 |
Rights issue.
|
| 15 Mar 2024 | Victor Previn | Issued | 1,233,948 | $259,129 |
Rights issue. As per announcement on 19-03-2024
|
| 15 Mar 2024 | Thomas (Tom) Spurling | Issued | 62,700 | $13,167 |
Rights issue.
|
| 15 Mar 2024 | Thomas (Tom) Spurling | Issued | 31,217 | $6,555 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Victor Previn | Executive DirectorExecutive Chairman | Jul 2001 |
Mr Previn's career spans more than 40 years in both the ophthalmic laser industry and the wider ophthalmic device sector. He is also a member of the Risk Committee.
|
| Mr Thomas (Tom) Anthony Spurling | Managing Director | Aug 2020 |
Mr Spurling served as the Chief Executive Officer of Ellex Medical Lasers from 2011 to 2019. He has 30 years of senior executive experience serving in a range of commercial and management roles in Australia and the United States.
|
| Mr Rahmon Coupe | Non-Executive Director | May 2013 |
Mr Coupe has 37 years of experience in the areas of corporate management, intellectual property management, contract negotiation, business development and engineering and has worked across a diverse range of industries, including information technology, life sciences and public broadcasting. He is also a member of the Risk Committee.
|
| Mr Mike Southard | Non-Executive Director | Dec 2019 |
Mr Southard spent 26 years with Alcon Laboratories of Fort Worth, Texas, as Vice President of the Global Surgical business. Mike is currently actively involved in ophthalmology, dermatology and orthopaedics through his consulting company based in Portland, Oregon, USA.
|
| Mr Daniel Webb | Non-Executive Director | Nov 2022 |
Mr Webb is based in Toronto, Canada and has a career that has spanned over 40 years in the marketing, sale, and distribution of medical devices. After spending 10 years in various positions in ophthalmic device sales, Dan commenced his career with the medical laser company Coherent. In 1990 Dan established Coherent-AMT, now known as Clarion Medical Technologies (Clarion) to import, market, sell and distribute a range of medical devices, focusing on ophthalmic, aesthetic, and surgical devices, in Canada.
|
| Mr Simon Ramsey Alexander Gray | Company Secretary | Jun 2020 |
-
|
| Simon Ramsey Alexander Gray | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| National Nominees Limited | 40,113,310 | 17.51% |
| J P Morgan Nominees Australia Pty Limited | 10,274,698 | 4.49% |
| Sedico Pty Ltd <Victor Previn Family A/C> | 8,175,353 | 3.57% |
| Ruminator Pty Ltd | 5,694,759 | 2.49% |
| Canala Super Fund Pty Ltd <Giuseppe Canala Sf A/C> | 4,515,857 | 1.97% |
| Citicorp Nominees Pty Limited | 3,519,291 | 1.54% |
| Highlands Investments Holdings Pty Ltd | 2,600,113 | 1.14% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 2,184,484 | 0.95% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 2,157,360 | 0.94% |
| Sean Barrett Pty Ltd <Super Fund A/C> | 2,030,000 | 0.89% |
| Super Wide Pty Ltd <Super Wide Super Fund A/C> | 1,900,717 | 0.83% |
| Dinwoodie Investments Pty Ltd | 1,856,714 | 0.81% |
| Mrs Glenis Nita O'Donnell | 1,800,465 | 0.79% |
| Toucan Trading Pty Ltd | 1,781,716 | 0.78% |
| Mr John Kwok Mun Yuen | 1,776,312 | 0.78% |
| BNP Paribas Noms Pty Ltd | 1,746,547 | 0.76% |
| Innovative Glaucoma Solutions Llc | 1,736,653 | 0.76% |
| Mr Anthony William Scott | 1,622,195 | 0.71% |
| HSBC Custody Nominees (Australia) Limited | 1,607,554 | 0.70% |
| Pine Street Pty Ltd <Pine Street A/C> | 1,406,250 | 0.61% |
